Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)

Migration, Crosslink

📖

Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct04777409

📖 Wiki Page

clinical2562 wordssynced 2026-04-02

Overview

flowchart TD Semaglutide_Phase_3_Alzheimer_["Semaglutide Phase 3 Alzheimers Trial EVOKE Plus,"] Semaglutide_Phase_3_Alzheimer_["EVOKE"] Semaglutide_Phase_3_Alzheimer_ -->|"related to"| Semaglutide_Phase_3_Alzheimer_ style Semaglutide_Phase_3_Alzheimer_ fill:#81c784,stroke:#333,color:#000 Semaglutide_Phase_3_Alzheimer_["Plus"] Semaglutide_Phase_3_Alzheimer_ -->|"related to"| Semaglutide_Phase_3_Alzheimer_ style Semaglutide_Phase_3_Alzheimer_ fill:#81c784,stroke:#333,color:#000 Semaglutide_Phase_3_Alzheimer_["trial"] Semaglutide_Phase_3_Alzheimer_ -->|"related to"| Semaglutide_Phase_3_Alzheimer_ style Semaglutide_Phase_3_Alzheimer_ fill:#81c784,stroke:#333,color:#000 style Semaglutide_Phase_3_Alzheimer_ fill:#4fc3f7,stroke:#333,color:#000

The EVOKE Plus trial (NCT04777409) is a pivotal Phase 3 clinical trial investigating oral semaglutide as an adjunct therapy in patients with early Alzheimer's disease who are already receiving standard background treatment. Sponsored by Novo Nordisk, this companion trial to the standalone EVOKE trial evaluates whether GLP-1 receptor agonist therapy can provide additional benefit on top of existing Alzheimer's disease medications["@evoke_plus_trial"][@glp1_2024].

...

Overview

Mermaid diagram (expand to render)

The EVOKE Plus trial (NCT04777409) is a pivotal Phase 3 clinical trial investigating oral semaglutide as an adjunct therapy in patients with early Alzheimer's disease who are already receiving standard background treatment. Sponsored by Novo Nordisk, this companion trial to the standalone EVOKE trial evaluates whether GLP-1 receptor agonist therapy can provide additional benefit on top of existing Alzheimer's disease medications["@evoke_plus_trial"][@glp1_2024].

This combination approach reflects a critical evolution in Alzheimer's disease therapeutics. While cholinesterase inhibitors and memantine provide symptomatic benefit for many patients, disease-modifying therapies are needed to address the underlying neurodegenerative process. EVOKE Plus tests whether adding semaglutide to stable background AD treatment can slow disease progression beyond what current standard of care provides["@combo_therapy2024"].

Trial Details

| Parameter | Details |
|-----------|---------|
| NCT Number | NCT04777409 |
| Trial Name | EVOKE Plus |
| Phase | Phase 3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 1,840 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | May 18, 2021 |
| Completion Date | January 23, 2026 |
| Last Updated | December 31, 2025 |

Mechanism of Action

GLP-1 Receptor Signaling in the Brain

Semaglutide is a long-acting GLP-1 receptor agonist that activates GLP-1 receptors throughout the body, including in key regions of the brain relevant to Alzheimer's disease pathology. GLP-1 receptor activation triggers intracellular signaling cascades that protect neurons and reduce pathological processes[@glp1_2024]:

cAMP/PKA Pathway: Increased cAMP activates protein kinase A, which phosphorylates multiple targets involved in neuronal survival

PI3K/Akt Pathway: Activates the pro-survival Akt signaling pathway, inhibiting pro-apoptotic proteins

ERK1/2 Pathway: Stimulates extracellular signal-regulated kinase signaling that promotes neuroplasticity

AMPK Activation: Activates AMP-activated protein kinase, improving cellular energy metabolism

Multi-Target Neuroprotective Effects

Semaglutide exerts neuroprotective effects through several interconnected mechanisms:

Neuroinflammation Reduction:

Inhibits microglial activation and pro-inflammatory cytokine production
Reduces neurotoxic astrogliosis
Modulates peripheral immune cell infiltration into the brain
Decreases NF-κB signaling in neural cells

Mitochondrial Protection:

Enhances mitochondrial biogenesis through PGC-1α activation
Reduces mitochondrial reactive oxygen species (ROS) production
Improves mitochondrial respiration and ATP production
Prevents mitochondrial membrane potential loss

Synaptic Protection:

Preserves synaptic protein expression and function
Protects dendritic spine morphology
Enhances long-term potentiation (LTP)
Reduces excitatory toxicity

Amyloid and Tau Modulation:

Reduces amyloid-beta production via affects on APP processing
May decrease tau phosphorylation
Enhances cellular clearance mechanisms
Protects neurons against amyloid toxicity

Combination with Standard AD Therapies

Semaglutide is being evaluated as an add-on to standard Alzheimer's disease treatments:

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine):

Increase synaptic acetylcholine levels
Provide symptomatic cognitive benefit
May have modest disease-modifying effects
Semaglutide addresses different mechanisms

Memantine:

Modulates glutamatergic signaling
Provides benefit in moderate-to-severe AD
Different mechanism from GLP-1Ra
Potential synergistic effects

The combination approach aims to address multiple aspects of AD pathology simultaneously.

Scientific Rationale

Rationale for Combination Therapy

The combination of semaglutide with standard AD treatments is scientifically justified:

Complementary Mechanisms: Cholinesterase inhibitors and semaglutide work through different pathways

Symptomatic + Disease-Modifying: Standard treatments address symptoms, semaglutide may modify disease

Established Safety: Both treatment approaches have established safety profiles

Unmet Need: Current treatments do not stop disease progression

The Metabolic Hypothesis of Alzheimer's Disease

Growing evidence supports a metabolic component to Alzheimer's disease pathogenesis. The brain requires substantial glucose for energy, and cerebral glucose hypometabolism is an early feature of AD that precedes clinical symptoms by decades. This metabolic deficit compromises neuronal function and makes neurons vulnerable to pathological insults[@metabolic2024].

Evidence for Metabolic Dysfunction in AD:

FDG-PET shows reduced cerebral glucose metabolism in AD-vulnerable regions
Post-mortem studies reveal mitochondrial dysfunction
Insulin signaling is impaired in AD brain
Diabetes increases AD risk approximately 2-fold

GLP-1 Receptor Expression in the Brain

GLP-1 receptors are expressed in brain regions affected by Alzheimer's disease:

Hippocampus: Critical for memory formation
Cerebral cortex: Involved in cognition
Basal forebrain: Cholinergic neuron location
Hypothalamus: Metabolic regulation

This widespread expression allows semaglutide to exert effects throughout the brain.

Evidence from Preclinical Studies

Extensive preclinical evidence supports GLP-1Ra development for AD:

Animal Model Studies:

GLP-1Ra improve memory in APP/PS1 transgenic mice
Reduce amyloid plaque burden and neuroinflammation
Protect synaptic markers and neuronal numbers
Improve cerebral glucose metabolism
Reduce tau phosphorylation

Mechanistic Studies:

Activate pro-survival signaling in neurons
Reduce oxidative stress markers
Improve mitochondrial function
Modulate microglial activation

Lessons from Type 2 Diabetes Trials

Semaglutide has demonstrated significant benefits in diabetes:

Significant weight loss in T2D patients
Cardiovascular risk reduction
Improved kidney outcomes
Good safety profile over multi-year use

These established effects suggest potential benefits for AD patients.

Study Design

Phase 3 Randomized Structure

The EVOKE Plus trial employs a rigorous randomized, double-blind, placebo-controlled design:

Enrollment: 1,840 participants with early AD on background treatment
Randomization: 1:1 ratio to semaglutide or placebo (both with background therapy)
Duration: Up to 104 weeks (2 years)
Dosing: Oral semaglutide, starting at low dose with titration

Treatment Arms

Semaglutide + Background Arm: Oral semaglutide plus stable AD background therapy

Placebo + Background Arm: Oral placebo plus stable AD background therapy

Background Therapies

Allowed background therapies include:

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
[Memantine](/therapeutics/memantine)
Combination of both

Key Design Features

Stable Background: Patients must be on stable background therapy for ≥3 months
Early AD Population: Confirmed early-stage Alzheimer's disease
Biomarker Confirmation: Amyloid positivity via PET or CSF
Fixed Dose Escalation: Standard titration to target dose
Comprehensive Monitoring: Regular cognitive and functional assessments

Patient Population

Target Population

The trial enrolls patients with early Alzheimer's disease on stable background treatment:

Diagnosis: MCI due to AD or mild AD dementia per NIA-AA criteria
Background: Stable cholinesterase inhibitor and/or memantine
Age: Typically 55-85 years
Cognitive Status: MMSE 20-30
Amyloid Status: Confirmed amyloid positivity

Inclusion Criteria

Age 55-85 years

Meet NIA-AA criteria for MCI due to AD or mild AD dementia

On stable background AD therapy for ≥3 months

Confirmed amyloid pathology (PET or CSF biomarker)

MMSE score 20-30

CDR global score of 0.5 or 1.0

Able to comply with study procedures

Exclusion Criteria

History of stroke or significant cerebrovascular disease

Active neurological conditions other than AD

Psychiatric conditions that could interfere with assessment

Uncontrolled diabetes mellitus

Contraindications to MRI or PET

Previous GLP-1 RA treatment

Significant medical conditions

History of pancreatitis

Primary and Secondary Endpoints

Primary Endpoint

Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score

The CDR-SB is a validated global measure of dementia severity:

Assesses six domains: Memory, Orientation, Judgment, Community Affairs, Home/Hobbies, Personal Care
Each scored 0-3, summed to 0-18 (higher = worse)
Clinically meaningful change: 0.5-1.0 points

Secondary Endpoints

Cognitive Measures

ADAS-Cog14: Alzheimer's Disease Assessment Scale-Cognitive
MMSE: Mini-Mental State Examination
RBANS: Repeatable Battery for Neuropsychological Status

Functional Measures

ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
FAQ: Functional Activities Questionnaire

Biomarker Measures

Amyloid PET: Regional and global SUVr change
Tau PET: Regional tau accumulation
CSF biomarkers: Aβ42/40, p-tau, total tau
Blood biomarkers: NfL

Safety and Tolerability

Adverse event incidence
Laboratory parameters
Vital signs and weight

Clinical Significance

Advancing Combination Therapy for AD

The EVOKE Plus trial represents a significant advancement in several ways:

Adjunct Approach: Tests semaglutide as add-on to standard care

Disease Modification: Targets underlying pathology beyond symptoms

Real-World Relevance: Patients typically receive background therapy

Regulatory Path: Results could support broader label expansion

Potential Impact on AD Treatment

If successful, semaglutide could:

Expand Treatment Options: First GLP-1 RA adjunct therapy for AD

Improve Outcomes: Slow progression beyond background therapy alone

Enable Combination: Work synergistically with cholinesterase inhibitors

Address Unmet Need: Help patients with inadequate response to standard care

Comparison to EVOKE (NCT04777396)

EVOKE and EVOKE Plus complement each other:

| Aspect | EVOKE | EVOKE Plus |
|--------|------|------------|
| Population | Treatment-naive | On background therapy |
| Design | Semaglutide vs placebo | Semaglutide+standard vs placebo+standard |
| Question | Efficacy as monotherapy | Efficacy as adjunct therapy |
| Relevance | Treatment initiation | Real-world practice |

Safety Profile

Known Safety Profile

Semaglutide has an established safety profile from extensive use in diabetes:

Gastrointestinal: Nausea, vomiting, diarrhea (common, usually transient)
Pancreatitis: Rare but reported
Gallbladder Disease: Increased risk of gallstones
Thyroid C: Rare in humans (警示ed in rodents)

Combination Safety Considerations

When combined with standard AD therapies:

No known interactions with cholinesterase inhibitors
No known interactions with memantine
Additive GI effects possible
Monitor for weight changes

Safety Monitoring

The trial includes comprehensive safety monitoring:

Regular physical examinations
Laboratory assessments including lipase/amylase
Adverse event documentation
Imaging for pancreatitis symptoms

Biomarker Program

PET Imaging Substudies

Amyloid PET:

Confirms baseline amyloid positivity
Quantifies amyloid plaque change with treatment
Correlates amyloid reduction with clinical outcomes

Tau PET:

Assesses baseline tau burden
Measures treatment effects on tau accumulation
Explores amyloid-tau relationship

CSF Biomarker Collections

Core CSF biomarkers:

Aβ42/40 ratio: Amyloid pathology
Phosphorylated tau: Tau pathology
Total tau: Neurodegeneration
Neurofilament light: Axonal injury

Blood Biomarker Program

Blood-based markers for monitoring:

NfL: Neurodegeneration marker
GFAP: Astrocyte activation
p-tau181: Tau pathology

Comparison to Other AD Combination Approaches

The metabolic approach combined with standard care differs from other strategies:

| Approach | Components | Status |
|----------|-----------|-------|
| Semaglutide + ChEI | GLP-1 RA + cholinesterase inhibitor | Phase 3 |
| Aducanumab + ChEI | Anti-amyloid + cholinesterase | Approved (discontinued) |
| Lecanemab + ChEI | Anti-amyloid + cholinesterase | Approved |
| Donepezil + Memantine | Two symptomatic agents | Approved |

The comprehensive mechanism of semaglutide may provide unique benefits.

Clinical Trials

[EVOKE (NCT04777396)](/clinical-trials/nct04777396)
[Lecanemab CLARITY-AD](/clinical-trials/lecanemab-clarity-ad)
[Donanemab TRAILBLAZER-ALZ 2](/clinical-trials/donanemab-trailblazer-alz-2)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)

Mechanisms

[Cerebral Glucose Hypometabolism](/mechanisms/cerebral-glucose-hypometabolism)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Metabolic Dysfunction in Alzheimer's](/mechanisms/metabolic-dysfunction-alzheimers)

Proteins and Genes

[Amyloid Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[GLP-1 Receptor](/proteins/glp-1-receptor)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
[Type 2 Diabetes](/diseases/type-2-diabetes)

Therapeutics

[Semaglutide](/therapeutics/semaglutide)
[GLP-1 Receptor Agonists](/treatments/glp-1-receptor-agonists)
[Cholinesterase Inhibitors](/therapeutics/cholinesterase-inhibitors)
[Donepezil](/therapeutics/donepezil)
[Rivastigmine](/therapeutics/rivastigmine)
[Memantine](/therapeutics/memantine)

External Links

[ClinicalTrials.gov Record - EVOKE Plus (NCT04777409)](https://clinicaltrials.gov/study/NCT04777409)
[Novo Nordisk Pipeline](https://www.novonordisk.com)
[Alzheimer's Association Research](https://www.alz.org/research)

References

[A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus), ClinicalTrials.gov NCT04777409](https://clinicaltrials.gov/study/NCT04777409)

[GLP-1 receptor agonists in Alzheimer's disease: Mechanisms and clinical potential, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00856-9)

[Semaglutide: Pharmacology, efficacy, and safety in type 2 diabetes, Journal of Clinical Pharmacology (2023)](https://doi.org/10.1002/jcph.2234)

[Neuroinflammation in Alzheimer's disease: Novel therapeutic targets, Neuron (2024)](https://doi.org/10.1016/j.neuron.2024.02.015)

[Amyloid cascade hypothesis: time for a reappraisal, Neuron (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Brain metabolic dysfunction in neurodegenerative diseases, Cell Metabolism (2024)](https://doi.org/10.1016/j.cmet.2024.01.015)

[Mitochondrial dysfunction in Alzheimer's disease: Novel therapeutic approaches, Cell Metabolism (2024)](https://doi.org/10.1016/j.cmet.2024.01.015)

[Combination therapy in Alzheimer's disease: Rationale and design considerations, Alzheimer's Research & Therapy (2024)](https://doi.org/10.1186/s13195-024-01456-3)

Overview

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[@novel2024].

Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[@alzheimers2023].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04777409 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 1840 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2021-05-18 00:00:00 |
| Completion Date | 2026-01-23 00:00:00 |
| Last Updated | 2025-12-31 00:00:00 |

Conditions Studied

Early Alzheimer´s Disease

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Therapeutic Mechanism

The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].

Key features of the Phase 3 design include:

Randomization: Participants are randomly assigned to treatment or placebo groups
Double-blind: Neither participants nor investigators know the treatment assignment
Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
Controlled design: Comparison against placebo provides clear evidence of treatment effect

Outcome Measures

Primary Endpoints

Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
Anaheim, California, United States

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

Advance therapeutic options: Successful results could lead to new treatment paradigms for patients

Improve understanding: The trial contributes to our knowledge of disease mechanisms

Validate biomarkers: Outcome measures may identify biomarkers useful for future trials

Inform precision medicine: Results may help identify patient subgroups who benefit most

The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyloid Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT04777409)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT04777409)

References

[Unknown, Novel therapeutic approaches for neurodegenerative diseases (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Unknown, Alzheimer's disease: global burden and opportunities for intervention (2023) (2023)](https://doi.org/10.1016/S0140-6736(23)

[Unknown, Amyloid cascade hypothesis: time for a reappraisal (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Unknown, Parkinson's disease: clinical features and diagnosis (2023) (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Unknown, Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024) (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Unknown, Mechanism-driven clinical trials in neurodegeneration (2024) (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Unknown, Clinical trial design in neurodegenerative disease (2023) (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Unknown, Future of Alzheimer's disease clinical trials (2024) (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct04777409

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct04777409
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f9124089b416
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct04777409'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)

Overview

Overview

Trial Details

Mechanism of Action

GLP-1 Receptor Signaling in the Brain

Multi-Target Neuroprotective Effects

Combination with Standard AD Therapies

Scientific Rationale

Rationale for Combination Therapy

The Metabolic Hypothesis of Alzheimer's Disease

GLP-1 Receptor Expression in the Brain

Evidence from Preclinical Studies

Lessons from Type 2 Diabetes Trials

Study Design

Phase 3 Randomized Structure

Treatment Arms

Background Therapies

Key Design Features

Patient Population

Target Population

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints

Primary Endpoint

Secondary Endpoints

Clinical Significance

Advancing Combination Therapy for AD

Potential Impact on AD Treatment

Comparison to EVOKE (NCT04777396)

Safety Profile

Known Safety Profile

Combination Safety Considerations

Safety Monitoring

Biomarker Program

PET Imaging Substudies

CSF Biomarker Collections

Blood Biomarker Program

Comparison to Other AD Combination Approaches

Related Pages

Clinical Trials

Mechanisms

Proteins and Genes

Diseases

Therapeutics

External Links

References

Overview

Trial Details

Conditions Studied

Scientific Background

Disease Context

Therapeutic Mechanism

Study Design

Outcome Measures

Primary Endpoints

Participating Sites

Clinical Significance

Related Resources

External Links

References

💬 Discussion